Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment for inflammation

A technology for a condition, arthritis, applied in the field of treatment of inflammatory diseases

Inactive Publication Date: 2008-02-27
CAN-FITE BIOPHARMA LTD
View PDF13 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This receptor is highly expressed in various tumor cell types but shows lower expression in adjacent normal tissues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment for inflammation
  • Treatment for inflammation
  • Treatment for inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0115] Example 1: In vivo studies

[0116] Material

[0117] A was synthesized by Albany Molecular Research Inc. (Albany, NY, USA) 3AR agonist CF101, GMP grade compound, generically known as 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl Base-D-ribofuranuramide (IB-MECA).

[0118] Methotrexate was purchased from Abie, Israel.

[0119] method

[0120] Female Lewis rats, 8-12 weeks old, were obtained from Harlan Laboratories (Jerusalem, Israel). Rats were fed standardized pelleted chow and provided with tap water. Experiments were performed in accordance with the guidelines established by the Institutional Animal Care and Use Committee of Can-Fite BioPharma, Petah Tikva, Israel. Rats were injected subcutaneously at the base of the tail with 100 μl of a suspension consisting of incomplete Freund's adjuvant (IFA) and 10 mg / ml heat-killed Mycobacterium tuberculosis (Mt) H37Ra (Difco, Detroit, USA). Each group contained 10 animals.

[0121] Treatment wi...

Embodiment 2

[0125] Example 2: In vitro studies

[0126] Culture of Human Fibroblast-Like Synoviocytes (FLS)

[0127] Human synovial fluid samples were collected from osteoarthritis (OA) patients undergoing paracentesis. The liquid was centrifuged and the supernatant was removed. Cells were resuspended in DMEM containing collagenase type I (4 mg / ml) for 2 hours with vigorous shaking at 37°C. Cells released in the supernatant were harvested by centrifugation and incubated at 37 °C, 5% CO 2 cultured in DMEM containing 10% FBS, 2mM glutamine, 100U / ml penicillin, 100μg / ml streptomycin, 1% non-essential amino acids, 1% sodium pyruvate and 20nM HEPES buffer. After overnight culture, non-adherent cells were removed. Adherent cells (FLS) were passaged at a 1:2 ratio, and cells from passages 4 to 10 were used in this experiment.

[0128] The effect of CF101 and methotrexate (MTX) together on the proliferation of FLS was examined using the MTT assay. Incubate cells in growth medium in 96-wel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Inflammatory state in a subject is assayed by determining the level of expression of A3 adenosine receptor (A3AR) in white blood cells (WBC), e.g. circulating WBCs, from the subject. A high level of expression of A3AR is indicative of an inflammatory state in the subject. This assay can be used for determining the severity of inflammation in a subject and monitoring the efficacy of anti-inflammatory treatment. Also, the level of expression may be used for selecting patients to receive an anti-inflammatory treatment that comprises an A3AR agonist.

Description

field of invention [0001] The present invention relates to the field of therapy and in particular to the treatment of inflammatory diseases. [0002] current technology [0003] The following is a list of technologies considered to be relevant to the state of the art in the field in which this invention is described. Citations of these references are sometimes indicated in this specification by indicating their number from the list below within parentheses. [0004] 1. Fishman P, et al. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene., 21 : 4060-4064 (2002). [0005] 2. Fishman P, Wait until Targeting the A3 adenosine receptor forcancer therapy: inhibition of Prostate carcinoma cell growth by A3AR agonist. Anticancer Res., 23 : 2077-2083(2003). [0006] 3. Madi L et al. A3adenosine receptor activation in melanomacells: association between receptor fate and tumor growth inhibition. J. Bio. Chem., 278 : 42121-42...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61P29/00
CPCG01N2800/52
Inventor P·菲什曼S·巴－耶胡达
Owner CAN-FITE BIOPHARMA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com